Jan Egberts, a pharmaceutical industry veteran, has been appointed to the newly-formed supervisory board of Netherlands-based Lead Pharma BV which is developing small molecule compounds that moderate pro-inflammatory proteins. Dr Egberts was most recently chief executive officer of Agendia Inc, a molecular diagnostics company.
Joining Dr Egberts on the board is Jan van der Hoeven, an entrepreneur and scientist known for his work on the relationship between food and cancer. Also joining the board is Daan van den Noort, a manager and venture capitalist. Mr van den Noort has been the general manager of the Dutch units of Genentech (Roche), Asta Medica GmbH and Ferring SA as well as the chief investment officer of the Biotech Turnaround Fund.
Lead Pharma announced the appointments on 18 June 2015.
Copyright 2015 Evernow Publishing Ltd